MLTX
MoonLake ImmunotherapeuticsCompany Information
- Company Name
- MoonLake Immunotherapeutics
- CIK
- CIK0001821586
- Category
- Large accelerated filer
- Ticker: Exchange
- MLTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MLTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-08
- Last sale
- 2026-07-27
- Shares purchased (TTM)
- 10,870
- Shares sold (TTM)
- 4,239,943
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 66,979,044
- Shares outstanding
- 73,915,296
- Ownership
- 90.62%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -13.39%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 478 | 298 | 335 | 351 | 307 | 272 | 180 | 376 | 343 | 458 | 451 | 318 | ||||||
| Available For Sale Securities Debt Securities Current | 59 | 59 | 59 | 30 | 118 | 209 | 268 | 118 | 177 | 89 | 60 | 178 | ||||||
| Other Receivables Net Current | 7 | 6 | 5 | 4 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | ||||||
| Prepaid Expense Current | 26 | 33 | 23 | 27 | 27 | 23 | 23 | 16 | 15 | 5 | 2 | 3 | ||||||
| Assets Current | 570 | 397 | 422 | 411 | 455 | 506 | 474 | 512 | 537 | 554 | 514 | 500 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 0 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | - | 0 | 2 | 4 | 6 | 8 | - | ||||||
| Property Plant And Equipment Net | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 2 | 2 | 0 | - | - | - | - | - | ||||||
| Assets Noncurrent | 4 | 4 | 3 | 3 | 5 | 5 | 4 | 6 | 8 | 11 | 12 | 0 | ||||||
| Assets | 574 | 400 | 424 | 414 | 460 | 511 | 478 | 518 | 545 | 564 | 527 | 500 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities And Other Liabilities | 27 | 22 | 15 | 22 | 9 | 11 | 12 | 8 | 6 | 4 | 7 | 7 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities Current | 45 | 46 | 45 | 48 | 27 | 24 | 22 | 20 | 12 | 9 | 10 | 10 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Long Term Debt | 100 | 99 | 74 | 74 | 73 | 73 | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 | ||||||
| Defined Benefit Pension Plan Liabilities Noncurrent | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | ||||||
| Liabilities Noncurrent | 100 | 100 | 74 | 75 | 75 | 75 | 2 | 3 | 3 | 3 | 3 | 0 | ||||||
| Liabilities | 146 | 146 | 120 | 123 | 102 | 99 | 25 | 23 | 15 | 12 | 13 | 11 | ||||||
Equity | ||||||||||||||||||
| Additional Paid In Capital | 1,022 | 786 | 767 | 689 | 684 | 681 | 677 | 675 | 672 | 670 | 610 | 531 | ||||||
| Retained Earnings Accumulated Deficit | -594 | -533 | -463 | -400 | -331 | -276 | -236 | -190 | -155 | -130 | -117 | -109 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 0 | 1 | 0 | 1 | 2 | 5 | 3 | 3 | 3 | 2 | 3 | ||||||
| Stockholders Equity | 428 | 254 | 304 | 291 | 358 | 408 | 447 | 496 | 530 | 552 | 496 | 425 | ||||||
| Minority Interest | - | - | 0 | 2 | 4 | 5 | 7 | 7 | 9 | 10 | 18 | 65 | ||||||
| Liabilities And Stockholders Equity | 574 | 400 | 424 | 414 | 460 | 511 | 478 | 518 | 545 | 564 | 527 | 500 | ||||||
| Common Class A | 0 | 0 | 72 | 0 | 0 | 63 | 0 | 0 | 0 | 63 | 0 | 0 | ||||||
| Common Class C | - | - | 0 | -0 | 0 | 1 | 0 | -0 | 0 | 1 | 0 | -0 | ||||||
| Common Stock | - | - | - | 64 | -63 | 63 | - | 0 | 0 | 63 | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMoonLake Immunotherapeutics (MLTX) — SEC Financial Statements & Analysis
MoonLake Immunotherapeutics (MLTX) is a pharmaceutical preparations company, incorporated in E9. MoonLake Immunotherapeutics trades on Nasdaq as: MLTX. MoonLake Immunotherapeutics (MLTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, MoonLake Immunotherapeutics carries a market cap of $1.44B, a P/E ratio of -5.48x, a P/B ratio of 3.36x, an enterprise value of $1.06B, and an EV/EBITDA multiple of -4.00x. On profitability, it posts a Return on Equity (ROE) of -66.87%, a Return on Assets (ROA) of -50.84%, and a Return on Invested Capital (ROIC) of -306.39%. Per share, it reports EPS of $-3.56, diluted EPS of $-3.56, free cash flow per share of $-3.05, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 49.17% year-over-year and EPS growth of 27.71% year-over-year. On the balance sheet, it maintains a current ratio of 12.56x, a quick ratio of 11.98x, working capital of $524.65M, a debt-to-equity ratio of 0.34x, a debt ratio of 0.25, an interest coverage ratio of -26.58x, free cash flow of $-225.18M (TTM), and net debt of $-378.39M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.44B
- P/E TTM
- -5.48x
- EPS TTM
- $-3.56
- P/B TTM
- 3.36x
- ROE TTM
- -66.87%
- ROA TTM
- -50.84%
- Debt To Equity
- 0.34x
- Free Cash Flow TTM
- $-225.18M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is MoonLake Immunotherapeutics in?
MoonLake Immunotherapeutics (MLTX) operates in the Pharmaceutical Preparations industry.
What exchange does MLTX trade on?
MoonLake Immunotherapeutics (MLTX) trades on the Nasdaq.
Where is MoonLake Immunotherapeutics incorporated?
MoonLake Immunotherapeutics is incorporated in Cayman Islands.
When was MoonLake Immunotherapeutics (MLTX)'s most recent SEC filing?
MoonLake Immunotherapeutics (MLTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is MLTX's market cap?
MoonLake Immunotherapeutics (MLTX) has a market capitalization of $1.44B as of 2026-06-30.
What is MLTX's EPS (earnings per share)?
MoonLake Immunotherapeutics (MLTX)'s trailing twelve month EPS is $-3.56 as of 2026-06-30.
What is MLTX's ROE (return on equity)?
MoonLake Immunotherapeutics (MLTX)'s trailing twelve month Return on Equity (ROE) is -66.87% as of 2026-06-30.
What is MLTX's ROA (return on assets)?
MoonLake Immunotherapeutics (MLTX)'s trailing twelve month Return on Assets (ROA) is -50.84% as of 2026-06-30.
What is MLTX's ROIC (return on invested capital)?
MoonLake Immunotherapeutics (MLTX)'s trailing twelve month Return on Invested Capital (ROIC) is -306.39% as of 2026-06-30.
What is MLTX's EV/EBITDA?
MoonLake Immunotherapeutics (MLTX)'s trailing twelve month EV/EBITDA is -4.00x as of 2026-06-30.